Colorectal cancer (CRC) is the third most common cancer and it is suspected to be linked to the western lifestyle. Indeed, the incidence for CRC in high-income countries such as United States, Japan, and Western Europe is 10-fold higher than that in low-income and middle-income countries ([@bib17]). Environmental factors that induce inflammation have been suggested to augment the growth of CRC. In the human gut, there are approximately 10^13^ commensal bacteria dominated by *Bacteroidetes*, *Firmicutes,* and *Proteobacteria* ([@bib3]). It has been suggested that imbalances in these bacterial populations may cause colitis that in turn proceeds to CRC. Indeed, long lasting inflammatory processes such as that found in Crohn\'s disease and ulcerative colitis are associated with a higher incidence of CRC ([@bib17]; [@bib14]).

Growth arrest and DNA damage-inducible protein 34 (GADD34/Ppp1r15a) was originally isolated based on ultraviolet-inducible transcripts in Chinese hamster ovary cells ([@bib3]). It belongs to a family of GADD genes that are induced by DNA damage ([@bib33]). Expression of GADD34 is also induced by amino-acid deprivation and several types of endoplasmic reticulum (ER) stresses ([@bib24]; [@bib27]; [@bib16]). [@bib15] demonstrated a correlation between the onset of apoptosis and GADD34 expression in selected cell lines following ionising irradiation or treatment with the alkylating agent methyl methanesulfonate. Later, GADD34 was shown to dephosphorylate several kinases that function in important signalling cascades. Two related genes, Ppp1r15a and Ppp1r15b, encoding the proteins GADD34 and CReP, respectively, recruit a catalytic subunit from one of several related protein phosphatase I (PP1) isoforms to form a holophosphatase complex that can dephosphorylate several enzymes *in vitro* ([@bib13]). Using GADD34-deficient (KO) mice, our laboratory and others have shown that GADD34 dephosphorylates the translation initiation factor eIF2*α* and inhibits the shut-off of protein translation ([@bib19]; [@bib28]). Furthermore, GADD34-PP1 dephosphorylates several signalling molecules that are engaged in inflammation or the host defense system. Viral or bacterial infections are affected by GADD34 including vesicular stomatitis virus ([@bib14]) and measles virus infection ([@bib9]; [@bib25]). GADD34 dephosphorylates IKK*β* ([@bib21]) and Tak1 ([@bib12]), which affect inflammatory signalling.

Because GADD34 contributes to apoptosis, ER stresses, and inflammation, we hypothesised that GADD34 could modify tumour initiation and inflammatory carcinogenesis. However, whether GADD34 would enhance or suppress tumour initiation and inflammation was unclear. To test this hypothesis, the azoxymethane/dextran sodium sulfate (AOM/DSS) system is ideal because AOM/DSS models have been widely used to study inflammation-dependent CRC ([@bib5]; [@bib10]). Here, we investigated the murine inflammatory colitis AOM/DSS model in GADD34KO mice.

Materials and methods
=====================

Mice
----

All experiments used 6- to 8-week-old wild-type (WT) and GADD34-deficient (GADD34KO) female mice born from the same mother, and maintained at the Animal Research Facility at Nagoya University Graduate School of Medicine under specific pathogen-free conditions. GADD34KO mice were generated as previously described ([@bib19]). Originally, GADD34KO mice were produced from ES cells with a C57BL/6 and 129 background. These mice were backcrossed to WT for up to 10 generations. This work was approved by the ethical committee of Nagoya University.

Induction of CRC
----------------

Mice were intraperitoneally injected with 12 mg kg^−1^ body weight of AOM (Sigma-Aldrich, St Louis, MO, USA) dissolved in phosphate-buffered saline (PBS). Five days after AOM administration, 2% DSS (MP Biomedicals, Santa Ana, CA, USA, molecular weight 35 000--50 000 kDa) was administered in the drinking water for 5 consecutive days (first round of DSS treatment). Subsequently, untreated water was given for 16 days. Then DSS was administered for 5 days followed by 16 days of pure water (second round of DSS treatment). Finally, DSS was administered for 4 days (third round of DSS treatment) ([Figure 1A](#fig1){ref-type="fig"}). Body weight was assessed at least 3 days per week throughout the course of the experiment.

DSS-induced colitis model
-------------------------

Acute colitis was induced with 2% DSS for 5 days followed by normal drinking water until the end of the experiment ([Figure 2A](#fig2){ref-type="fig"}).

Histopathological analysis
--------------------------

Mouse colon tissues were prepared as Swiss rolls, fixed in 4% paraformaldehyde in neutral buffer solution for paraffin embedding. Paraffin-embedded tissues were cut into 4-*μ*m sections and stained with haematoxylin and eosin (H&E). Histology scores were determined as described in a previous report ([@bib32]). These scores were assigned as follows, based on the extent and severity of inflammation, ulceration, and hyperplasia of the mucosa in the distal colon.

*Inflammation*: 0=normal; 1=mild (small, focal, or widely separated, limited to the lamina propria); 2=moderate (multifocal or locally extensive, extending to submucosa); 3=severe (transmural inflammation with ulcers covering \>20 crypts).

*Ulceration*: 0=normal; 1=mild (1 or 2 ulcers involving up to a total of 20 crypts); 2=moderate (1 to 4 ulcers involving a total of 20--40 crypts); 3=severe (\>4 ulcers or over 40 crypts).

*Hyperplasia*: 0=normal; 1=mild (crypts 2 to 3 times normal thickness, normal epithelium); 2=moderate (crypts 2 to 3 times normal thickness, hyperchromatic epithelium, reduced goblet cells, scattered arborisation); 3=severe (crypt \>4 times normal thickness, marked hyperchromasia, few to no goblet cells, high mitotic index, frequent arborisation).

*Extent*: 0=normal (0% involvement); 1=mild (up to 30% involvement); 2=moderate (30--70% involvement); 3=severe (over 70% involvement).

Real-time PCR analysis
----------------------

Total RNA was isolated using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer\'s recommended protocol. Residual genomic DNA was digested and removed using DNase I (Invitrogen, Waltham, MA, USA) treatment. First-strand cDNA was synthesised using 1 *μ*g total RNA and a High Capacity cDNA Reverse Transcription Kit (Applied BioSystems, Waltham, MA, USA) for real-time PCR. Real-time PCR was performed using SYBR green (Toyobo, Osaka, Japan) according to the manufacturer\'s instructions. Expression data were normalised to *Gapdh* mRNA expression. The primer sequences are shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Cytokines from serum and supernatants from cultured colon tissue
----------------------------------------------------------------

Serum samples and distal colons were taken from naïve or DSS-treated WT and GADD34KO mice. Colon tissues were cultured in serum-free RPMI medium containing penicillin/streptomycin for 24 h and cultured supernatants were collected. IL-6 and TNF*α* protein in serum and in cultured colon supernatants was determined by specific ELISA kits according to the manufacturer\'s instructions (R&D Systems, Minneapolis, NE, USA).

Western blot analysis and immunohistochemistry
----------------------------------------------

Tissue samples were homogenised in standard RIPA buffer with PMSF. The protein concentration was determined with a DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA). Lysates (30 *μ*g protein) were separated by 6--10% SDS-gel electrophoresis, and transferred onto PVDF membranes (Millipore, Darmstadt, Germany). Membranes were blocked in PBST buffer containing 3% skim milk for 1 h at room temperature, probed with primary antibodies and secondary HRP-conjugated antibodies (GE Healthcare, Little Chalfont, UK), and developed using the ECL Western blot detection reagents (GE Healthcare).

Paraffin-embedded slides were deparaffinised, and boiled in citrate buffer for antigen retrieval and stained overnight with anti-IL-6 (Abcam, Cambridge, UK; 1 : 400 dilution), anti-p-STAT3 (Cell Signaling, Danvers, MA, USA; 1 : 400 dilution) or anti-Ki67 (Santa Cruz, Santa Cruz, CA, USA; 1 : 200 dilution) antibodies. TUNEL staining was performed using an *In Situ* Apoptosis Detection Kit (Takara, Shiga, Japan). The TUNEL-stained slides were analysed with a Nikon A1RSi Laser Scanning Confocal Microscope (Nikon, Tokyo, Japan).

Immunofluorescence analysis
---------------------------

Colon tissues from mice were embedded in OCT compound (Sakura Finetek, Tokyo, Japan). Four-micrometer sections were fixed in 4% paraformaldehyde. After rinsing with PBS, sections were permeabilised and treated with blocking buffer (0.2% Triton X-100, 0.2% bovine serum albumin (BSA) and 0.1% normal goat serum in PBS). FITC-conjugated anti-IL-6 (eBioscience, Santa Clara, CA, USA), APC-conjugated anti-F4/80 (eBioscience) and Cy3-conjugated anti-*α*-SMA (Sigma-Aldrich) were used at 1 : 500 dilutions and incubated at 4 °C overnight, after which sections were washed with PBS and incubated with 4,6-diamidino-2-phenylindole (DAPI) for 5 min. After rinsing with PBS, the sections were mounted with mounting fluid and visualised under A1Rsi inverted Confocal Microscopy (Nikon).

Lamina propria cell isolation
-----------------------------

Colons were opened longitudinally, cut into fine pieces, and incubated with Hanks\' balanced salt solution (HBSS) containing 5 m[M]{.smallcaps} EDTA for 15 min at 37 °C to remove epithelial cells. Colonic pieces without epithelial cells were then incubated with PBS containing 4% fetal bovine serum (FBS), 0.5 mg ml^−1^ collagenase typeII, 1 mg ml^−1^ dispase and 50 *μ*g ml^−1^ DNase for 20 min at 37 °C. The cells were washed twice and suspended in PBS.

Flow-cytometric analyses and cell sorting
-----------------------------------------

The cells were washed twice and cells (1 × 10^6^) were suspended in 50 *μ*l PBS supplemented with 1% FBS and stained for 20 min at 4 °C with directly conjugated fluorescent antibodies (1 : 500). Antibodies were as follows: eFluor450-conjugated anti-CD11b (eBioscience); FITC-conjugated anti-Gr-1 (BD Biosciences, Franklin Lakes, NJ, USA); APC-conjugated anti-Gr-1 (eBioscience); FITC-conjugated anti-CD11c (eBioscience). Stained cells were analysed with a FACS Canto flow cytometer using FACS Diva software (BD Biosciences), and the data were analysed with FlowJo software (TreeStar, Ashland, OR, USA). Cells were sorted with a FACS Aria flow cytometer (BD Biosciences) and washed twice and suspended in PBS. Cells (2 × 10^5^) were resuspended in 100 *μ*l PBS and centrifuged onto microscope slides using a Cytospin-4 (Thermo Scientific, Waltham, MA, USA). Slides were then stained by May-Grunwald Giemsa according to a standard protocol.

Reactive oxygen species production analysis
-------------------------------------------

Flow cytometry was used to measure intracellular reactive oxygen species (ROS) accumulation with 5-(and 6-)-chloromethyl-2\',7\'-dichilorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Invitrogen). Isolated lamina propria cells were incubated in RPMI medium (Sigma-Aldrich) containing 5 *μ*[M]{.smallcaps} CM-H2DCFDA for 30 min at 37 °C in the dark. Fluorescence was analysed with a FACS Canto flow cytometer as described previously.

Statistical analyses
--------------------

Data are expressed as means±standard error of the mean (s.e.m.). Differences were analysed by Student\'s *t*-test. *P*-values less than 0.05 were considered as statistically significant.

Results
=======

GADD34 promoted tumour formation in a mouse colitis-associated cancer model
---------------------------------------------------------------------------

To assess the role of GADD34 in tumour formation, WT and GADD34-deficient (GADD34KO) mice were treated with AOM and three rounds of DSS ([Figure 1A](#fig1){ref-type="fig"}). Changes in body weight were monitored three times per week throughout the study duration and colonic tumour burden was determined 62 days after AOM/DSS treatment. Body weight loss in GADD34KO mice was significantly less than that in WT mice ([Figure 1B](#fig1){ref-type="fig"}). GADD34KO mice had a significantly lower tumour burden in the colon ([Figure 1C and D](#fig1){ref-type="fig"}), and the number of large tumours was lower than in WT mice ([Figure 1D](#fig1){ref-type="fig"}). We found that *Gadd34* gene expression was upregulated in the colon, especially epithelial cells of tumour-bearing mice ([Supplementary Figure 1a and b](#sup1){ref-type="supplementary-material"}). Histological examination of tumours was evaluated by staining. The tumour grade of WT mice was higher than that of GADD34KO mice ([Figure 1E and F](#fig1){ref-type="fig"}). About 60% of tumours were classified as high grade adenomas and adenocarcinomas in WT mice, and about 40% were classified as high grade adenomas and adenocarcinomas in GADD34KO mice ([Figure 1F](#fig1){ref-type="fig"}).

GADD34 increased the severity of experimental colitis
-----------------------------------------------------

To investigate the role of GADD34 in colitis-induced inflammation, WT and GADD34KO mice were fed 2% DSS in drinking water for 5 days, after which they were given normal drinking water ([Figure 2A](#fig2){ref-type="fig"}). They were killed during the acute (day 5) and recovery (days 10 and 19) stages. *Gadd34* mRNA expression was significantly upregulated at day 10 ([Figure 2B](#fig2){ref-type="fig"}). Upregulation of *Gadd34* expression was detected in both immune cells and epithelial cells ([Supplementary Figure 1c](#sup1){ref-type="supplementary-material"}). Histopathological analysis revealed that WT mice had more severely damaged colonic mucosa, as evidenced by the loss of crypt structure and hyperplasia, larger areas of ulceration, and more extensive infiltration of inflammatory cells than GADD34 KO mice ([Figure 2C and D](#fig2){ref-type="fig"}).

GADD34 promoted epithelial growth through the IL-6-STAT3 axis
-------------------------------------------------------------

In WT colon, one round of DSS treatment led to immune cell infiltration and enhancement of mRNA expression for pro-inflammatory mediators, including *Il-6*, *Tnfα*, *Il-1β*, and *Nos2/inos*. Expression of these genes was higher in WT mice than in GADD34KO mice ([Figure 3A](#fig3){ref-type="fig"}). IL-6 and TNF*α* protein levels in sera and cultured supernatants of colon tissue were also higher in WT mice than those in GADD34KO mice ([Figure 3B and C](#fig3){ref-type="fig"}). Strong iNOS/NOS2 protein expression was confirmed in WT mice but not in GADD34KO mice ([Figure 3D and E](#fig3){ref-type="fig"}). These results suggest that GADD34 increased the severity of experimental colitis through upregulating pro-inflammatory mediators.

Next, we examined NF*κ*B, STAT and MAPK signalling pathways that induce the expression of pro-inflammatory genes following one round of DSS. We observed high expression of p-STAT3 protein that correlated with IL-6 expression in WT mice ([Figure 3D and E](#fig3){ref-type="fig"}). The expression of p-STAT3 was lower in GADD34 KO mice than in WT mice. However, the expression of p-NF*κ*B p65 and p-I*κ*B*α* was not significantly different between WT and GADD34 KO mice ([Figure 3D and E](#fig3){ref-type="fig"}). On the other hand, we observed higher expression of members of the MAPK signalling pathway, p-ERK and p-JNK (46 kDa) in WT mice than those in GADD34 KO mice ([Figure 3F and G](#fig3){ref-type="fig"}), although p-p38 expression was not increased by one round of DSS treatment in either WT or GADD34KO mice ([Figure 3F and G](#fig3){ref-type="fig"}).

We then asked whether immune cells and/or epithelial cells could produce pro-inflammatory cytokines. To solve the question, cells were assessed by immunohistochemistry for production of IL-6. We observed that IL-6 was mainly produced by infiltrating cells in DSS-treated mice. The expression of cytosolic IL-6 was higher in WT mice than in GADD34KO mice ([Figure 4A](#fig4){ref-type="fig"}). Using immunofluorescent staining, we found that IL-6 was mainly produced by F4/80-positive macrophages but not *α*-SMA-positive fibroblasts ([Figure 4B](#fig4){ref-type="fig"}). IL-6 may induce STAT3 signalling by binding to epithelial cells. We observed clear expression of p-STAT3 in colon epithelial cells. The expression of intracellular p-STAT3 was higher in WT mice than in GADD34KO mice ([Figure 4C and D](#fig4){ref-type="fig"}). Moreover, GADD34 promoted colon epithelial proliferation as detected by Ki-67 staining in the AOM/DSS-induced colitis model ([Figure 4E and F](#fig4){ref-type="fig"}).

GADD34 deficiency attenuated the recruitment of pro-inflammatory myeloid cells
------------------------------------------------------------------------------

The expression of inflammatory cytokines by immune cells indicated that myeloid cell infiltration was underway during DSS-induced colitis. DSS may damage colon epithelial cells, a process that can induce chemokines. Chemokine genes such as *Mcp1*, *Cxcl2*, and *Cxcr2* and *Csf3* (granulocyte-colony stimulating factor) were highly expressed in WT mice after DSS treatment. Expression of those genes was lower in GADD34 KO mice than in WT mice ([Figure 5A](#fig5){ref-type="fig"}). Gr-1^high^/CD11b^high^ neutrophils and CD11b+/CD11c− macrophages were highly recruited to the colons of DSS-treated WT mice. Infiltration of these cells was less pronounced in GADD34KO colons ([Figure 5B and C](#fig5){ref-type="fig"}). In DSS-treated colon, myeloid cells produced ROS. The expression of ROS following DSS treatment was higher in WT mice than in GADD34KO mice ([Figure 5D and E](#fig5){ref-type="fig"}). We observed high ROS production in Gr-1^high^/CD11b^high^ neutrophils ([Figure 5F and G](#fig5){ref-type="fig"}). Taken together, these results indicated that GADD34 had a critical role in promoting the inflammatory response following DSS-induced injury of the colonic epithelium.

Effect of GADD34 on AOM treatment
---------------------------------

Next, we investigated the effect of GADD34 on the administration of AOM alone. Azoxymethane and its precursor compound 1, 2-dimethylhydrazine (DMH) are alkylating agents in the liver and colon. They cause DNA mutation by binding alkyl or methyl groups to guanine residues, resulting in G-to-A transition mutations ([@bib8]). Azoxymethane (12 mg kg^−1^) was injected intraperitoneally into WT and GADD34KO mice. *Gadd34* mRNA expression was observed 24 h after AOM treatment ([Supplementary Figure 2a](#sup1){ref-type="supplementary-material"}). Histological examination 24 h after AOM administration revealed that the pathological changes were weak and no differences between WT and GADD34KO mice were detected ([Supplementary Figure 2b](#sup1){ref-type="supplementary-material"}). Because AOM induces DNA damage, we examined p-p53 expression. We found that the level of p-p53 was enhanced by the administration of AOM both in WT and in GADD34KO mice. The expression of p-p53 did not differ between WT and GADD34KO mice ([Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}). We also examined the expression of p-eIF2*α* (ER stress marker), p-NF*κ*B and p-STAT3 (inflammatory signalling) proteins. The expression of these proteins was not readily observed in either WT or GADD34KO mice ([Supplementary Figure 2c](#sup1){ref-type="supplementary-material"}). The expression levels of IL-6 (an inflammatory cytokine) and CHOP and ATF4 (ER stress markers) were slightly increased by the administration of AOM but there were no differences between WT and GADD34KO mice ([Supplementary Figure 2d](#sup1){ref-type="supplementary-material"}).

AOM/DSS treatment-induced inflammation
--------------------------------------

Finally, we examined the effects of GADD34 on AOM/DSS treatment. WT and GADD34KO mice were injected with 12 mg kg^−1^ AOM and the animals were given normal drinking water. Five days after AOM treatment, they were fed 2% DSS for 5 days in drinking water after which they were given normal drinking water ([Figure 6A](#fig6){ref-type="fig"}). They were killed at day15, and the severity of colitis and pro-inflammatory mediator production was analysed. The loss of body weight was slightly greater in WT mice than in GADD34KO mice ([Figure 6B](#fig6){ref-type="fig"}). Compared with GADD34KO mice, WT mice had more severely damaged colonic mucosa, with loss of crypt structures and hyperplasia, larger areas of ulceration and more extensive infiltration of inflammatory cells ([Figure 6C and D](#fig6){ref-type="fig"}). In WT mice, AOM with one round of DSS treatment induced pro-inflammatory mediators (IL-6, TNF*α*, and iNOS/NOS2) but all of them were downregulated in GADD34KO mouse colons ([Figure 6E](#fig6){ref-type="fig"}). Additionally, GADD34 promoted colon epithelial proliferation as detected by Ki-67 staining in the AOM/DSS-induced colitis model ([Figure 6F](#fig6){ref-type="fig"}).

Discussion
==========

Here, we have shown that GADD34 expression enhanced CRC tumorigenesis. Moreover, we found that DSS-induced inflammatory responses were downregulated by GADD34 deficiency. Expression levels of pro-inflammatory cytokines such as TNF*α*, IL-6, and IL-1*β* were higher in WT mice than in GADD34KO mice. Inflammatory conditions have been shown to promote oncogene transformation and tumour progression ([@bib23]). It is particularly interesting that IL-6 was continuously expressed in the colon during the course of AOM/DSS treatment. A correlation between IL-6 levels and the clinical activity of inflammatory bowel disease (IBD) and CRC has been demonstrated ([@bib4]). IL-6 binds to its receptor (IL-6R*α*) that in turn interacts with gp130 and activates Janus kinases (JAK) and STAT3 ([@bib18]). The IL-6/STAT3 cascade is an important regulator of the proliferation of tumour cells ([@bib11]; [@bib31]). It was recently shown that TLRs are expressed by gut epithelial cells, and they induce protective roles against microbes, including the production of pro-inflammatory cytokines ([@bib1]). We identified the main cells that produced pro-inflammatory cytokines following the administration of DSS. Specifically, we showed here that DSS treatment induced IL-6 production in myeloid cells that migrated to the DSS-damaged colonic tissue. Further, we found that p-STAT3 was expressed in DSS-damaged colonic epithelial cells. These expression levels were higher in WT mice than in GADD34KO mice. In fact, not only IL-6, but also TNF*α*, IL-1*β*, and NO production was greatly enhanced in WT mice. In the DSS colitis model, NO radicals induce TLR-4 signalling ([@bib30]). Increased iNOS in human ulcerative colitis ([@bib26]) and colon adenoma has been reported ([@bib2]; [@bib20]).

GADD34 has been shown to affect pathogen-induced innate immune responses. [@bib7] showed that GADD34 expression has positive effects on IL-6 and IFN*β* production in dendritic cells stimulated by poly (I:C). In contrast, there are reports that GADD34 expression has negative effects on pro-inflammatory cytokines. [@bib21] showed that CUEDC2 suppressed the activation of IKK through recruitment of GADD34/PP1 and downregulated NF*κ*B signalling that in turn suppressed pro-inflammatory cytokine production. Although NF*κ*B signalling is the main pathway that enhances mRNA expression for pro-inflammatory cytokines, we could not detect differences in NF*κ*B signalling between WT and GADD34KO mice stimulated with DSS ([Figure 3D and E](#fig3){ref-type="fig"}). We detected higher expression of MAPK signalling pathways in WT mice than in GADD34KO mice ([Figure 3F and G](#fig3){ref-type="fig"}).

ER stress is linked to the pathogenesis of IBD ([@bib29]; [@bib6]). However, our data revealed that DSS or AOM/DSS treatment did not clearly enhance p-eIF2*α* expression in either WT or GADD34KO colons ([Supplementary Figures 2c and 3a](#sup1){ref-type="supplementary-material"}). Expression of CHOP or ATF4 was not increased by DSS treatment in either WT or GADD34KO colons ([Supplementary Figure 3b](#sup1){ref-type="supplementary-material"}).

Recently, it was documented that GADD34KO mice showed earlier recovery than WT mice in a skin wound healing model ([@bib22]). They demonstrated that GADD34 inhibited myofibroblast differentiation through its inhibition of the Smad3-dependent TGF-*β* signal pathway and by promoting apoptosis by activating the caspase-3 pathway. However, we could not detect differences in apoptosis, p-smad2/3, or TGF-*β* expression or *α*-SMA-positive areas between WT and GADD34KO mice after DSS treatment ([Supplementary Figure 4a--e](#sup1){ref-type="supplementary-material"}). Instead, DSS treatment induced stronger recruitment of macrophages and neutrophils to damaged colon tissues in WT than in GADD34KO mice, and those cells produced pro-inflammatory cytokines, including IL-6 ([Figure 5B and C](#fig5){ref-type="fig"}).

Taken together, DSS treatment induced GADD34 expression that paralleled the expression of inflammatory cytokines and iNOS. In particular, IL-6/STAT3 signalling and JNK and ERK signalling were enhanced. Thus, GADD34 deficiency prevented the activation of IL-6/STAT3 signalling and signalling by JNK and ERK. As a result, the levels of pro-inflammatory cytokines were lower, and iNOS production was reduced, as were inflammatory responses and epithelial growth in AOM/DSS-induced colitis. This study demonstrated that GADD34 promoted AOM/DSS-induced carcinogenesis by enhancing IL-6 production from myeloid cells and subsequent STAT3 activation in epithelial cells.
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![**GADD34 promoted tumour formation in a mouse colitis-associated cancer model.** (**A**) Schematic diagram of AOM/DSS-induced colitis-associated colon cancer model. (**B**) Body weight changes. Body weight at day 0=100%. Data represent means±s.e.m. (*n*=6). (**C**) After AOM injection, mice were killed on day 62 to determine tumour development in the colon. (**D**) Upper: Number of tumours in the whole colon (day 62). Lower: Number of small tumours (\<2 mm) and large tumours (\>2 mm) in the whole colon. (**E**) Representative images of H&E staining of tumours and normal regions. Scale bar: 300 *μ*m. (**F**) Left: Overall grading of dysplasia in each genotype. Right: Representative high magnification images showing dysplasia in colon tissue. Scale bar: 300 *μ*m. Data are means±s.e.m. (WT: *n*=10, GADD34KO: *n*=8). \**P*\<0.05; \*\**P*\<0.01.](bjc2015263f1){#fig1}

![**GADD34 increased the severity of experimental colitis.** (**A**) Schematic diagram of mice treated with DSS. (**B**) Real-time PCR analysis for *Gadd34* mRNA in whole distal colon collected from WT mice at the indicated day. (**C**) Low magnification (upper) and high magnification (lower) of H&E staining of colon tissues taken from DSS-treated mice at days 0, 5, 10, and 19. Black arrows: ulceration, yellow arrows: hyperplasia, blue arrows: infiltration. Scale bar: 300 *μ*m. (**D**) Semiquantitative scoring of histopathology. Data represent means±s.e.m. (*n*=7). \**P*\<0.05. A full color version of this figure is available at the *British Journal of Cancer* journal online.](bjc2015263f2){#fig2}

![**GADD34 regulated the production of pro-inflammatory mediators in experimental colitis.** (**A**) Expression of pro-inflammatory mediator genes (*Il-6, Tnfα, Il-1β, Nos2/inos*) in whole distal colon was analysed by real-time PCR. (**B**) Serum cytokine levels (IL-6 and TNF*α*) were measured by ELISA. (**C**) Colon cytokine production (IL-6 and TNF*α*). Distal colons were taken from naïve or DSS-treated WT/GADD34KO mice and cultured in serum-free RPMI medium containing penicillin/streptomycin for 24 h. The supernatants were assessed by ELISA. (**D**--**G**) Whole colon tissues collected at days 0, 5, 10, and 19 were processed for western blot analysis. Representative data are shown in (**D** and **F**); quantitation of western blotting analysis is shown in (**E** and **G**). Data represent means±s.e.m. (*n*=7). \**P*\<0.05.](bjc2015263f3){#fig3}

![**GADD34 promoted colon epithelium growth through upregulating IL-6 production.** (**A**) Distal colons from DSS-treated mice (day 10) of both genotypes were stained with anti-IL-6. Scale bars: 100 *μ*m (**B**) Immunofluorescence analysis of DSS-treated WT mice. Blue: DAPI, Green: IL-6, Pink: F4/80 (macrophages), Red: *α*-SMA (fibroblasts). Scale bar: 25 *μ*m. (**C**--**F**) Distal colons from DSS-treated mice (day 10) of both genotypes were stained with anti-p-STAT3 (**C**) and anti-Ki-67 antibodies (**E**). Scale bar: 50 *μ*m (**C** and **E**). Black arrows show p-STAT3-positive intestinal epithelial cells (**C**). Number of p-STAT3-positive epithelial cells (**D**) and Ki-67-positive cells (**F**) were counted 10 days after DSS treatment. Data represent means±s.e.m. (*n*=6). \**P*\<0.05, \*\**P*\<0.01. A full color version of this figure is available at the *British Journal of Cancer* journal online.](bjc2015263f4){#fig4}

![**GADD34 enhanced recruitment of neutrophils and macrophages.** (**A**) Gene expression of chemokines (*Mcp1, Cxcl2*), a chemokine receptor (*Cxcr2*), and *Ccf3* (*G-CSF*) was analysed in whole distal colon by real-time PCR. Colons were taken from naïve and DSS-treated mice (day 10). Data represent means±s.e.m. (*n*=6). (**B**) Representative flow-cytometric data plot of lamina propria-infiltrating cells. Lamina propria cells were collected at day 5 of 3% DSS treatment. Data are representative of three experiments (each experiment included two or three mice/group). (**C**) The numbers of Gr-1^high^/CD11b^high^ cells, dendritic cells (DCs; CD11b+/CD11c+), and macrophages (Macs; CD11b+/CD11c−) were determined by flow-cytometric analysis. Lamina propria cells were collected at day 5 of 3% DSS treatment. Data represent means±s.e.m. (*n*=6). (**D** and **E**) ROS production from lamina propria-infiltrating cells at day 5 of 3% DSS treatment was measured by flow-cytometric analysis. Mean fluorescence intensity is shown in (**E**). Data represent means±s.e.m. (*n*=6). (**F**) ROS production from Gr-1^high^/CD11b^high^ cells at day 5 of 3% DSS treatment was measured by flow-cytometric analysis. Statistical graph represents the percentage of ROS-positive cells in the Gr-1^high^/CD11b^high^ population. Data represent means±s.e.m. (*n*=6). (**G**) May-Giemsa staining of the Gr-1^high^/CD11b^high^ population from DSS-treated bone marrow. Scale bar: 50 *μ*m. \**P*\<0.05, \*\*\**P*\<0.001.](bjc2015263f5){#fig5}

![**GADD34 promoted epithelial growth after one round of AOM/DSS treatment.** (**A**) Schematic diagram of mice treated with AOM/DSS. (**B**) Body weight changes. Body weight at day 0=100%. Data represent means±s.e.m. (*n*=8). (**C**) H&E staining of colon tissues taken from AOM/DSS-treated mice at day 15. Black arrows: ulceration; yellow arrows: hyperplasia; blue arrows: infiltration. Scale bar: 300 *μ*m. (**D**) Semiquantitative scoring of histopathology at day 15 of AOM/DSS treatment. (**E**) Whole colon gene expression of pro-inflammatory mediators (*Il-6*, *Tnfα*, *Nos2/inos*) was analysed by real-time PCR. (**F**) Left: Colonic tissues from AOM/DSS-treated colitis mice (day 15) were collected and immunostained for the proliferation marker Ki-67. Scale bar: 50 *μ*m. Right: Number of Ki-67-positive cells 10 days after DSS treatment. Data are means±s.e.m. (*n*=6). \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.A full color version of this figure is available at the *British Journal of Cancer* journal online.](bjc2015263f6){#fig6}
